Prevail Therapeutics Inc (PRVL)


Stock Price Forecast

Jan. 21, 2021


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Prevail Therapeutics Inc chart...

About the Company

We do not have any company description for Prevail Therapeutics Inc at the moment.

Exchange

NASDAQ/NMS (GLOBAL MARKET)

$M

Total Revenue

55

Employees

$759M

Market Capitalization

-9.96

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PRVL News

Eli Lilly to Buy Prevail Therapeutics in $1.04 Billion Deal, Shares Soar

3y ago, source: FXEmpire.com

According to the deal, Lilly will commence a tender offer to acquire all outstanding shares of Prevail Therapeutics Inc. for a purchase price of $22.50 per share in cash. The deal is expected to ...

E-mini S&P 500 Index (ES) Futures Technical Analysis – Strengthens Over 3664.00, Weakens Under 3645.25

3y ago, source: FXEmpire.com

In stock related news, Eli Lilly and Co rose 2.1% after the company said it would buy Prevail Therapeutics Inc in a deal potentially valued at $1.04 billion, to expand its presence in the ...

Omega Therapeutics Inc OMGA

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

DMAC DiaMedica Therapeutics Inc.

15h ago, source: Seeking Alpha

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company ...

CMPX Compass Therapeutics, Inc.

1d ago, source: Seeking Alpha

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States.

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

1d ago, source: TMCnet

"2023 was a transformative year for Precision BioSciences as we fully transitioned to our core capability as an in vivo gene editing company rapidly advancing development of our wholly owned in vivo ...

Seres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023

23d ago, source: Yahoo Finance

Warning! GuruFocus has detected 8 Warning Signs with MCRB. On March 5, 2024, Seres Therapeutics Inc (NASDAQ:MCRB) released its 8-K filing, announcing the fourth quarter and full year financial ...

Q4 2023 Amicus Therapeutics Inc Earnings Call

28d ago, source: Yahoo Finance

Bradley Campbell; President, CEO; Amicus Therapeutics, Inc. Sébastien Martel; Chief Business Officer; Amicus Therapeutics, Inc. Jeff Castelli; Chief Development ...

Monopar Therapeutics Inc

3mon ago, source: CNN

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development ...

Akero Therapeutics Inc (AKRO)

13d ago, source: Investing

Jonathan Young, the Chief Operating Officer of Akero Therapeutics, Inc. (NASDAQ:AKRO), has recently sold shares of the company's common stock, generating over $18,000 in the... Akero Therapeutics ...

Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant Review

1d ago, source: TMCnet

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to developing and commercializing innovative therapeutics to treat seizure disorders, today affirmed its commitment to ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...